Assembly Biosciences, Inc. (ASMB)
NASDAQ: ASMB · Real-Time Price · USD
26.11
-2.85 (-9.84%)
Sep 15, 2026, 4:00 PM EDT - Market closed
Assembly Biosciences Revenue
Assembly Biosciences had revenue of $13.37M in the quarter ending June 30, 2026, with 38.94% growth. This brings the company's revenue in the last twelve months to $74.85M, up 125.12% year-over-year. In the year 2025, Assembly Biosciences had annual revenue of $72.30M with 153.52% growth.
Revenue (ttm)
$74.85M
Revenue Growth
+125.12%
P/S Ratio
7.10
Revenue / Employee
$1,025,274
Employees
73
Market Cap
531.62M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 72.30M | 43.78M | 153.52% |
| Dec 31, 2024 | 28.52M | 21.36M | 298.16% |
| Dec 31, 2023 | 7.16M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 6.25M | -72.85M | -92.09% |
| Dec 31, 2020 | 79.11M | 63.14M | 395.55% |
| Dec 31, 2019 | 15.96M | 1.16M | 7.83% |
| Dec 31, 2018 | 14.80M | 5.79M | 64.14% |
| Dec 31, 2017 | 9.02M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 462.25M |
| Valneva SE | 163.30M |
| OmniAb | 38.46M |
| Allogene Therapeutics | 4.64M |
| Oculis Holding AG | 1.45M |
| Shattuck Labs | 1.00M |
| Altimmune | 31.00K |
ASMB News
- 5 days ago - Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference - GlobeNewsWire
- 7 days ago - Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program - GlobeNewsWire
- 14 days ago - Assembly Biosciences price target raised to $53 from $45 at Mizuho - TheFly
- 14 days ago - Assembly Biosciences initiated with a Buy at UBS - TheFly
- 4 weeks ago - Assembly Biosciences reports Q2 EPS (20c), consensus (52c) - TheFly
- 4 weeks ago - Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates - GlobeNewsWire
- 4 weeks ago - Assembly Biosciences Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Assembly Biosciences Earnings release: Q2 2026 - Filings